Alerts will be sent to your verified email
Verify Email
AMBALALSA
|
Ambalal Sarabhai Ent
|
Gennex Lab
|
Lyka Labs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
0.01 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
19.11 % | 8.73 % | 68.98 % |
|
5yr average Equity Multiplier
|
2.07 | 1.48 | 2.9 |
|
5yr Average Asset Turnover Ratio
|
0.75 | 0.67 | 0.73 |
|
5yr Avg Net Profit Margin
|
10.89 % | 9.84 % | -0.79 % |
|
Price to Book
|
1.61 | 1.12 | 2.18 |
|
P/E
|
21.52 | 13.61 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-37.53 Days | 55.46 Days | 32.55 Days |
|
Inventory Days
|
33.51 Days | 55.63 Days | 24.2 Days |
|
Days Receivable
|
63.69 Days | 37.35 Days | 92.33 Days |
|
Days Payable
|
147.98 Days | 68.33 Days | 106.74 Days |
|
5yr Average Interest Coverage Ratio
|
9.88 | 6.72 | 2.2 |
|
5yr Avg ROCE
|
24.01 % | 11.78 % | 25.83 % |
|
5yr Avg Operating Profit Margin
|
5.29 % | 11.73 % | 24.02 % |
|
5 yr average Debt to Equity
|
0.32 | 0.18 | 1.25 |
|
5yr CAGR Net Profit
|
-30.01 % | 35.01 % | n/a |
|
5yr Average Return on Assets
|
8.69 % | 5.92 % | 1.72 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.36 % | 23.63 % | 58.16 % |
|
Share Pledged by Promoters
|
0.0 | 17.42 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.59 % | 0.25 % | 7.16 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -3.3 % |
|
Ambalal Sarabhai Ent
|
Gennex Lab
|
Lyka Labs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|